Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28614
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuang, Warren-
dc.contributor.authorWhitelaw, Jack-
dc.contributor.authorKishore, Kartik-
dc.contributor.authorNeto, Ary Serpa-
dc.contributor.authorHolmes, Natasha E-
dc.contributor.authorMarhoon, Nada-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorEkinci, Elif I-
dc.date2021-09-27-
dc.date.accessioned2022-01-18T04:46:30Z-
dc.date.available2022-01-18T04:46:30Z-
dc.date.issued2021-12-
dc.identifier.citationJournal of Diabetes and Its Complications 2021; 35(12): 108052en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28614-
dc.description.abstractTo compare the outcomes of sodium glucose linked cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP4i) in hospitalized patients. Electronic medical records-based cohort study. Identification of patients with type 2 diabetes and treatment with SGLT2i (n = 466) or DPP4i (n = 1541). Outcomes compared between those who received SGLT2i and those who received DPP4i. The primary outcome: adjusted percentage of blood glycemia within 4-10 mmol/L. After adjustment, SGLT2i use had a statistically equivalent percentage of glycemia within range (coefficient: 4.55, 95% CI -3.23 to 12.32, p = 0.25) or <4 mmol/L (coefficient -0.17, 95% CI -0.71 to 3.72, p = 0.54). There were no significant differences in hospital length of stay (p = 0.22), complications, (p = 0.11) or mortality (p = 0.57). When measured, ketone levels were higher in the SGLT2i group on admission, but lower on days 3, 4 and 5 (p < 0.001 for interaction). Bicarbonate levels were not statistically different between groups. Finally, 54% of patients whose SGLT2i was ceased during admission, were discharged home without it. Among inpatients with type 2 diabetes, SGLT2i use was associated with equivalent within-target glycaemia and no significant increase in hypoglycemia, ketonemia, or lower bicarbonate levels. These hypothesis-generating findings support further investigation of SGLT2i therapy in inpatients.en_US
dc.language.isoeng
dc.subjectComplicationsen_US
dc.subjectDPP4ien_US
dc.subjectEfficacyen_US
dc.subjectInpatienten_US
dc.subjectSGLT2ien_US
dc.subjectSafetyen_US
dc.titleThe comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Diabetes and Its Complicationsen_US
dc.identifier.affiliationData Analytics Research and Evaluation (DARE) Centre..en_US
dc.identifier.affiliationIntensive Careen_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Melbourne, Australia..en_US
dc.identifier.affiliationSchool of Medicine, The University of Melbourne, Melbourne, Australia.en_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.affiliationDepartment of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil..en_US
dc.identifier.affiliationDepartment of Critical Care, The University of Melbourne, Melbourne, Australia..en_US
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre Monash University, Melbourne, Australia..en_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34600824/en_US
dc.identifier.doi10.1016/j.jdiacomp.2021.108052en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-1650-8939en_US
dc.identifier.orcid0000-0001-8501-4054en_US
dc.identifier.orcid0000-0003-2372-395Xen_US
dc.identifier.orcid0000-0002-2636-4203en_US
dc.identifier.orcid0000-0003-1520-9387en_US
dc.identifier.pubmedid34600824
local.name.researcherBellomo, Rinaldo
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Jun 12, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.